Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CMP Clear all
Terminated Early Phase 1 Interventional

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

NCT03179956
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Ribociclib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 20, 2026, 9:27 PM EDT
Recruiting No phase listed Observational

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
TKIs
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
17
States / cities
Birmingham, Alabama • Stockton, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 9:27 PM EDT
Withdrawn Phase 4 Interventional

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

NCT04382625
View directory record Official record
Conditions
SARS-CoV-2 Pneumonia, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Kootenai Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Non-Invasive Blood Test Cross-Validation Study

NCT03991637
View directory record Official record
Conditions
Reproducibility of Results, Safety Issues
Interventions
Non-Invasive Comprehensive Metabolic Panel
Device
Lead sponsor
Joseph Allen Jr.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 20, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540
View directory record Official record
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions
AMG 397, Dexamethasone, Azacitidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 20, 2026, 9:27 PM EDT
Active, not recruiting Not applicable Interventional

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589
View directory record Official record
Conditions
Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
2 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 20, 2026, 9:27 PM EDT
Active, not recruiting No phase listed Observational

Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

NCT05344599
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Acute Hepatic Porphyria
Interventions
Autonomic Function Testing, Genetic Testing, Urine Testing, Blood laboratory Testing
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

NCT00423865
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

NCT02129582
View directory record Official record
Conditions
Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelofibrosis, Myeloproliferative Syndrome
Interventions
total marrow irradiation, fludarabine phosphate, busulfan, myeloid progenitor cell transplantation, anti-thymocyte globulin, tacrolimus, methotrexate, laboratory biomarker analysis
Radiation · Drug · Procedure + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Evaluation of Pain Neuroscience Education for Patients Who Experience Chronic Pain With Concurrent Opioid Dependence

NCT06442306
View directory record Official record
Conditions
Chronic Pain, Opioid Dependence
Interventions
Pain Neuroscience Education, General Health Education
Other
Lead sponsor
Wichita State University
Other
Eligibility
18 Years to 95 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exogenous Ketones in Healthy Young Adults

NCT03452761
View directory record Official record
Conditions
Healthy Young Adults
Interventions
Ketone Salts
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

NCT03143816
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Technosphere insulin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Casinomacropeptide and Satiety

NCT01587911
View directory record Official record
Conditions
Lack of Satiety, Excess Intake of Macronutrients, Appetite Disorders
Interventions
Whey, Whey-CMP, Control, CMP, MPI, CPI
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 20, 2026, 9:27 PM EDT
Recruiting Not applicable Interventional

This Project is a Three-arm RCT Evaluating Two, Single-session Behavioral Interventions for Adults With Chronic Musculoskeletal Pain (CMP) -- 1) Brief Mindfulness-Oriented Recovery Enhancement (B-MORE) vs. Empowered Relief (ER) -- Relative to the Traditional 8-week Version of MORE.

NCT07193095
View directory record Official record
Conditions
Chronic Musculoskeletal Pain
Interventions
Brief Mindfulness Oriented Recovery Enhancement, Empowered Relief, Mindfulness Oriented Recovery Enhancement
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Boluses of Ringer's in Surgical Kids (BRiSK Study)

NCT05285371
View directory record Official record
Conditions
Dehydration in Children, Fluid Therapy
Interventions
Urinalysis (UA), Complete Metabolic Panel (CMP), Glucose Stick Test (d-Stick), Medical Chart Review
Diagnostic Test · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 21 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 9:27 PM EDT
Active, not recruiting Phase 4 Interventional

Accelerated ART Initiation for PWHIV Who Are Out of Care

NCT06374758
View directory record Official record
Conditions
HIV Infections, ART, Noncompliance, Patient
Interventions
The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 20, 2026, 9:27 PM EDT
Terminated No phase listed Observational

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

NCT00883636
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
Interventions
Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
Other
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 20, 2026, 9:27 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Comparing the Effects of Lactated Ringers and Normal Saline in Acute Pancreatitis

NCT03242473
View directory record Official record
Conditions
Pancreatitis
Interventions
Fluid Management
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
0 Years to 18 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 20, 2026, 9:27 PM EDT
Completed No phase listed Observational

Uric Acid Levels and Endothelial Functions

NCT02862522
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Questionnaire of overall health
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older · Female only
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

NCT00853697
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant, Metastatic
Interventions
testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 20, 2026, 9:27 PM EDT
Terminated Phase 1 Interventional

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

NCT05107856
View directory record Official record
Conditions
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Interventions
PRT1419, Azacitidine, Venetoclax
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 20, 2026, 9:27 PM EDT